Gastroenterology
Volume 137, Issue 2 , Pages 482-488 , August 2009

Antidiabetic Therapies Affect Risk of Pancreatic Cancer

  • Donghui Li

      Affiliations

    • Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Corresponding Author InformationReprint requests Address requests for reprints to: Donghui Li, PhD, Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030. fax: (713) 834-6153
    • ,
  • Sai–Ching J. Yeung

      Affiliations

    • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Manal M. Hassan

      Affiliations

    • Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Marina Konopleva

      Affiliations

    • Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • James L. Abbruzzese

      Affiliations

    • Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Received 9 January 2009 ,Accepted 9 April 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Anderson K, Mack TM, Silverman DT. Cancer of the pancreas. In:  Schottenfeld D,  Fraumeni JF editor. Cancer epidemiology and prevention. 3rd ed.. New York, NY: Oxford University Press; 2006;p. 721–762
  3. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95–101
  4. Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134:981–987
  5. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer (A meta-analysis). JAMA. 1995;273:1605–1609
  6. Huxley RA, Ansary-Moghaddam A, de Gonzalez B, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076–2083
  7. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591
  8. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007;132:2208–2225
  9. Jones J, Clemmons D. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3–34
  10. Ding X-Z, Fehsenfeld DM, Murphy LO, et al. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas. 2000;21:310–320
  11. Berstein LM. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett. 2005;224:203–212
  12. Evans JMM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304–1305
  13. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254–258
  14. Dilman VM, Berstein LM, Zabezhinski MA, et al. Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary glands of rats. Arch Geschwulstforsch. 1978;43:1–8
  15. Anisimov VN, Semenchenko AV, Yashin AI. Insulin and longevity: antidiabetic biguanides as geroprotectors. Biogerontology. 2003;4:303–313
  16. Bonnefont-Rousselot D, Raji B, Walrand S, et al. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism. 2003;52:586–589
  17. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27:3576–3586
  18. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology. 2001;120:1263–1270
  19. Hassan MM, Wolff RA, Bondy ML, et al. Risk factors for pancreatic cancer: synergy of smoking with family history of pancreatic cancer and diabetes mellitus. Am J Gastroenterol. 2007;102:2696–2707
  20. Spitz MR, Fueger JJ, Newell GR. The development of a comprehensive, institution-based patient risk evaluation program: II (Validity and reliability of questionnaire data). Am J Prev Med. 1988;4:188–193
  21. American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care. 2008;31:S12–S54
  22. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137:25–33
  23. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs. 2003;63:1879–1894
  24. Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct pathways. J Biol Chem. 2002;277:25226–25232
  25. Hadad SM, Fleming S, Thompson AM. Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hemat. 2008;67:1–7
  26. Williams T, Brenman JE. LKB1 and AMPK in cell polarity and division. Trends Cell Biol. 2008;18:193–198
  27. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269–10273
  28. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67:6745–6752
  29. Anisimov VN, Egormin PA, Bershtein LM, et al. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med. 2005;139:721–723
  30. Cavanaugh KL, Merkin SS, Plantinga LC, et al. Accuracy of patients' reports of comorbid disease and their association with mortality in ESRD. Am J Kidney Dis. 2008;52:118–127
  31. Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev. 2006;15:1458–1463
  32. Silverman DT, Schiffman M, Everhart J, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer. 1999;80:1830–1837

 Conflicts of interest The authors disclose no conflicts.

 Funding Supported by National Institutes of Health R01 grant CA98380 (to D.L.), SPORE P20 grant CA101936 (to J.L.A.), and a multidisciplinary research program grant from M. D. Anderson Cancer Center (to S.J.Y.).

PII: S0016-5085(09)00555-1

doi: 10.1053/j.gastro.2009.04.013

Gastroenterology
Volume 137, Issue 2 , Pages 482-488 , August 2009

Article Tools